Vitamin D for pulmonary arterial hypertension
Part of Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests whether vitamin D supplements can help people with pulmonary arterial hypertension (high blood pressure in the lungs) who also have very low vitamin D levels. Participants will receive vitamin D or a placebo to see if it improves their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a specific type of pulmonary arterial hypertension (PAH) that is not caused by other diseases.
- Your PAH is stable and you are on standard treatments (like sildenafil or bosentan) with no changes in the last 6 weeks.
- Your risk from PAH is intermediate (not low or very high).
- Your vitamin D level is very low (12 ng/mL or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called XBD173 to see if it can reduce blood vessel inflammation and lower pressure in the lungs of people with pulmonary arterial hypertension (PAH). If you have a PAH diagnosis, are on two or more PAH medications, and already have a heart and lung monitor implanted, this study may be an option for you.
This study looks at stored blood samples to see if vitamin D and parathyroid hormone levels are linked to how well patients with pulmonary hypertension do. It may help find better ways to predict outcomes.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This trial studies whether adding vitamin D can help people with chronic heart failure who have low vitamin D levels. You may be eligible if your heart’s pumping strength is reduced and your treatment has been stable, and you meet certain risk factors.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Hear when a new Pulmonary Artery Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.